Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.82 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.74 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.73 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.67 |
| ▸ | THRA | P10827 | 1/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | RARB | P10826 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31661137 | 1.00 | KMT2A (0.82) | KMT2APLA2G4BSMPD1PLA2G2ANR1H4 | |
| SCHEMBL4652291 | 1.00 | KMT2A (0.82) | KMT2APLA2G4BSMPD1PLA2G2ANR1H4 | |
| SCHEMBL8080220 | 1.00 | KMT2A (0.82) | KMT2APLA2G4BSMPD1PLA2G2ANR1H4 | |
| SCHEMBL15766225 | 1.00 | KMT2A (0.82) | KMT2APLA2G4BSMPD1PLA2G2ANR1H4 | |
| SCHEMBL7822821 | 1.00 | KMT2A (0.82) | KMT2APLA2G4BSMPD1PLA2G2ANR1H4 | |
| SCHEMBL8081150 | 1.00 | KMT2A (0.82) | KMT2APLA2G4BSMPD1PLA2G2ANR1H4 | |
| SCHEMBL8082044 | 1.00 | KMT2A (0.82) | KMT2APLA2G4BSMPD1PLA2G2ANR1H4 | |
| SCHEMBL8086388 | 1.00 | KMT2A (0.82) | KMT2APLA2G4BSMPD1PLA2G2ANR1H4 | |
| SCHEMBL2887568 | 1.00 | KMT2A (0.82) | KMT2APLA2G4BSMPD1PLA2G2ANR1H4 | |
| SCHEMBL29758526 | 1.00 | KMT2A (0.82) | KMT2APLA2G4BSMPD1PLA2G2ANR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016058991-A1 | POLYMERS FEATURING ENHANCED FLOW | SOLVAY SPECIALTY POLYMERS USA, LLC (US) | 2016-04-21 | — | — | WO | claimed |
| JP-7258170-A | — | — | None | — | — | JP | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2018204764-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION (US) | 2018-11-08 | — | — | WO | disclosed |
| US-9475750-B2 | Phenylketone carboxylate compounds and pharmaceutical uses thereof | PROMETIC BIOSCIENCES INC. (CA) | 2016-10-25 | — | — | US | disclosed |
| US-9439882-B2 | Compounds and compositions for the treatment of cancer | PROMETIC BIOSCIENCES INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| WO-2016058991-A1 | POLYMERS FEATURING ENHANCED FLOW | SOLVAY SPECIALTY POLYMERS USA, LLC (US) | 2016-04-21 | — | — | WO | disclosed |
| US-20150313856-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC PHARMA SMT LIMITED (GB) | 2015-11-05 | — | — | US | disclosed |
| EP-0676652-A2 | Optical compensatory sheet and liquid crystal display | FUJI PHOTO FILM CO., LTD. (JP) | 1995-10-11 | — | — | EP | disclosed |
| JP-H07258170-A | NOVEL TRIPHENYLENE DERIVATIVE | FUJI PHOTO FILM CO LTD | 1995-10-09 | — | — | JP | disclosed |
| US-5385917-A | Treating androgen dependent diseases | MITSUBISHI KASEI CORPORATION (JP) | 1995-01-31 | — | — | US | disclosed |
| EP-0579223-A1 | Carboxylic acid derivatives having 5 alpha-reductase inhibitory activity | Mitsubishi Chemical Corporation (JP) | 1994-01-19 | — | — | EP | disclosed |
| US-5140046-A | Slow reacting substance of anaphylaxis antagonists | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-08-18 | — | — | US | disclosed |
| US-5116853-A | SRS-Antagonist, Antiallergens | MASE TOSHIYASU (JP) | 1992-05-26 | — | — | US | disclosed |
| EP-0425134-A1 | Condensed pyrrolo derivatives, process for their preparation and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
| US-4994479-A | Antagonists of SRS-A(slow reacting substance of anaphylaxis); antiallergens, antiischemic agents | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| EP-0218728-A1 | PHENYLENE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1987-04-22 | — | — | EP | disclosed |
| WO-1986005779-A1 | PHENYLENE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313856-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | DCK, TOP2B, TOP2A | KMT2A 1361/4885PLA2G4B 3993/4885SMPD1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.